| Aug 11 |
Atea Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 11 |
Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript
|
| Aug 7 |
Atea Pharmaceuticals GAAP EPS of -$0.48 beats by $0.29
|
| Aug 7 |
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 31 |
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
|
| Jun 5 |
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
|
| May 29 |
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
|
| May 22 |
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
|
